The RCAT Challenge: A Hidden Opportunity

The Respiratory Clinical Assessment Tool (RCAT) is a valuable tool for assessing respiratory risk. However, its reliance on patient recall and subjective clinical judgment can lead to inaccuracies. This presents a significant challenge for pharmaceutical companies seeking to identify and target high-risk patient populations for respiratory diseases.

The Cost of Inaccurate Respiratory Risk Assessment

Inaccurate respiratory risk assessment can lead to:

• Delayed diagnosis of respiratory conditions
• Ineffective treatment plans
• Increased healthcare costs
• Missed opportunities for preventative interventions

These consequences can significantly impact patient outcomes and hinder the development and commercialization of respiratory therapies.

Kribado: Your Solution to the RCAT Challenge

Kribado is a revolutionary patient screening device designed to enhance respiratory risk assessment. By providing rapid and accurate risk scores, Kribado empowers healthcare providers to:

• Identify high-risk patients early
• Optimize patient management
• Improve clinical trial recruitment
• Drive data-driven decision-making

How Kribado Works

Kribado’s user-friendly interface and advanced algorithms streamline the patient screening process. With a simple touch-screen and embedded printer, healthcare professionals can:

• Collect patient data efficiently
• Generate instant RCAT-based risk scores
• Stratify patients based on risk levels
• Inform personalized treatment plans